200 related articles for article (PubMed ID: 37033665)
1. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis.
Deng Z; Wang S; Wu C; Wang C
Front Pharmacol; 2023; 14():1124628. PubMed ID: 37033665
[No Abstract] [Full Text] [Related]
2. IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase.
Petitpain N; D'Amico F; Yelehe-Okouma M; Jouzeau JY; Netter P; Peyrin-Biroulet L; Gillet P
Clin Pharmacol Ther; 2021 Jul; 110(1):159-168. PubMed ID: 33411953
[TBL] [Abstract][Full Text] [Related]
3. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.
Fieldhouse KA; Ukaibe S; Crowley EL; Khanna R; O'Toole A; Gooderham MJ
Drugs Context; 2020; 9():. PubMed ID: 32362930
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study.
Deng Z; Wang S; Wu C
Front Pharmacol; 2023; 14():1197470. PubMed ID: 37849732
[No Abstract] [Full Text] [Related]
7. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Puig L; Davis M; Nunag D; Pinter A; Imafuku S
Dermatol Ther (Heidelb); 2024 Jan; 14(1):99-114. PubMed ID: 38019410
[TBL] [Abstract][Full Text] [Related]
10. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
11. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
12. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
13. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
Wright S; Alloo A; Strunk A; Garg A
J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
[TBL] [Abstract][Full Text] [Related]
14. Colitis induced by IL-17A-inhibitors.
Grümme L; Dombret S; Knösel T; Skapenko A; Schulze-Koops H
Clin J Gastroenterol; 2024 Apr; 17(2):263-270. PubMed ID: 38060157
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
16. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive testing in the management of children with suspected inflammatory bowel disease.
Dilillo D; Zuccotti GV; Galli E; Meneghin F; Dell'Era A; Penagini F; Colella G; Lewindon P; Carmagnola S; Farina E; Ardizzone S; Maconi G
Scand J Gastroenterol; 2019 May; 54(5):586-591. PubMed ID: 31032665
[No Abstract] [Full Text] [Related]
18. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
Liu Y; Chen Y; Zeng Z; Liu A
Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
[TBL] [Abstract][Full Text] [Related]
19. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
20. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
